Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.34 |
| ▸ | ESRRG | P62508 | 2/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | ESRRB | O95718 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10738378 | 0.85 | CYP1A2 (0.34) | GPR84DAO | |
| SCHEMBL10737487 | 0.85 | TAAR1 (0.34) | GPR84 | |
| SCHEMBL10739591 | 0.82 | CYP2C19 (0.41) | KCNH2DAO | |
| SCHEMBL10745565 | 0.75 | TAAR1 (0.41) | GPR84DAO | |
| SCHEMBL14839515 | 0.75 | ADRB2 (0.44) | KCNH2GRIA4SLC13A5ESRRGDAO | |
| SCHEMBL10737688 | 0.74 | TAAR1 (0.38) | GPR84DAO | |
| SCHEMBL9121119 | 0.74 | FAAH (0.45) | — | |
| SCHEMBL6944501 | 0.73 | CYP11B1 (0.30) | — | |
| SCHEMBL10745306 | 0.72 | ACP1 (0.34) | — | |
| SCHEMBL10740003 | 0.72 | ESR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888309-B1 | IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY | ORION CORP (FI) | 2003-03-19 | — | — | EP | disclosed |
| US-6479530-B2 | SUBSTITUTED 4(5)-(1-INDANYL,-INDANYLMETHYL, INDANYLMETHYLEN), 4(5)-(1-(1,2,3,4-TETRAHYDRONAPHTHYL, -NAPHTHYLMETHYL AND NAPHTHYLMETHYLEN)IMIDAZOLES; HYPOTENSIVE, ISCHEMIC AND ANXIOLYTIC AGENTS; NERVOUS AND MUSCULAR SYSTEM DISORDERS | ORION CORPORATION (FI) | 2002-11-12 | — | — | US | disclosed |
| US-20020007074-A1 | Imidazole derivatives having affinity for alpha2 receptors | KARJALAINEN ARTO (FI) | 2002-01-17 | — | — | US | disclosed |
| US-6313311-B1 | ADRENERGIC STIMULANTS FOR POTENTIATING ANESTHETICS PRIOR TO SURGERY; HYPOTENSIVE AGENTS, ANALGESICS, ANTIISCHEMIC AGENTS; NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | ORION CORPORATION (FI) | 2001-11-06 | — | — | US | disclosed |
| CN-1068592-C | Imidazole derivatives having affinity for alpha 2 receptors activity | ORION YHTYMAE OY (FI) | 2001-07-18 | — | — | CN | disclosed |
| EP-0888309-A1 | IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY | ORION CORPORATION (FI) | 1999-01-07 | — | — | EP | disclosed |
| CN-1198741-A | Imidazole derivatives having affinity for alpha 2 receptor activity | ORION YHTYMAE OY (FI) | 1998-11-11 | — | — | CN | disclosed |
| WO-1997012874-A1 | IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY | Orion-Yhtymä Oy (FI) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007074-A1 | Imidazole derivatives having affinity for alpha2 receptors | CHRM1, CHRNA1, CNR1 | KCNH2 78/4885SIGMAR1 75/4885GPR84 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.